Please login to the form below

Not currently logged in
Email:
Password:

rociletinib

This page shows the latest rociletinib news and features for those working in and with pharma, biotech and healthcare.

FDA okays Clovis' Lynparza rival rucaparib

FDA okays Clovis' Lynparza rival rucaparib

The company has been pummelled in recent months after an FDA advisory panel voted against a quick approval of its lung cancer candidate rociletinib, a decision that eventually prompted the company

Latest news

  • FDA panel says no to quick approval of Clovis' rociletinib FDA panel says no to quick approval of Clovis' rociletinib

    FDA panel says no to quick approval of Clovis' rociletinib. Recommends waiting for phase III trial results after "serious" safety concerns. ... An FDA advisory committee all but dashed any hopes that Clovis Oncology had for quick approval of its lung

  • AZ sets price of new lung cancer drug Tagrisso AZ sets price of new lung cancer drug Tagrisso

    The FDA has asked for more data on the drug - called rociletinib - which could potentially hold up the programme by several months. ... The FDA's problems with the dataset for rociletinib hinge on the number of unconfirmed versus confirmed responses to

  • Boehringer takes third-generation NSCLC drug into pivotal trials Boehringer takes third-generation NSCLC drug into pivotal trials

    chemotherapy. Aside from Boehringer, other companies developing third-generation EGFR inhibitors include Clovis Oncology with twice-daily rociletinib (CO-1686) and AZ with once-daily osimertinib/AZD9291, both of which are ... Clinical data on both

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics